PURPOSE: To test the hypothesis that autoantibodies against retinal pericytes could develop in diabetic retinopathy, and that these autoantibodies could induce retinal pericyte dysfunction/death via complement. METHODS: Human primary retinal pericytes cultured in media containing normal (5 mM) or high (30 mM) glucose concentrations were incubated with normal human sera in the presence of a retinal pericyte-reactive antibody, then their viability was assessed by a BCECF-based cytotoxicity assay, and their function was assessed by a T-cell proliferation assay. The pericytes were also analyzed by RT-PCR and flow cytometry to detect CD38, an established diabetes-associated cell surface autoantigen. The potential of the anti-CD38 antibodies in inducing pericyte cellular injury was evaluated using the same cytotoxicity assays. In addition, autoantibody-mediated cytotoxicity in mouse retinal pericytes sensitized by sera from mice with developing diabetic retinopathy or control normal mice were also studied. RESULTS: Retinal pericyte-reactive antibodies induced cellular damage by activating complement in the serum. The antibody-injured pericytes had reduced efficacy in inhibiting T cells. Hyperglycemic culture conditions rendered pericytes more susceptible to antibody-mediated attack. CD38 was expressed in retinal pericytes, and upregulated by TNF-α and IFN-γ, and anti-CD38 antibodies induced pericyte cytotoxicity. Retinal pericytes sensitized with sera from chronic diabetic mice suffered significantly augmented cytotoxicity compared with those sensitized with sera from the control mice. CONCLUSIONS: The autoantibody-initiated complement activation could be a mechanism underlying the loss of function, and eventually, death of retinal pericytes in diabetic patients, suggesting that inhibiting complement activation could be a novel therapeutic approach.
PURPOSE: To test the hypothesis that autoantibodies against retinal pericytes could develop in diabetic retinopathy, and that these autoantibodies could induce retinal pericyte dysfunction/death via complement. METHODS:Human primary retinal pericytes cultured in media containing normal (5 mM) or high (30 mM) glucose concentrations were incubated with normal human sera in the presence of a retinal pericyte-reactive antibody, then their viability was assessed by a BCECF-based cytotoxicity assay, and their function was assessed by a T-cell proliferation assay. The pericytes were also analyzed by RT-PCR and flow cytometry to detect CD38, an established diabetes-associated cell surface autoantigen. The potential of the anti-CD38 antibodies in inducing pericyte cellular injury was evaluated using the same cytotoxicity assays. In addition, autoantibody-mediated cytotoxicity in mouse retinal pericytes sensitized by sera from mice with developing diabetic retinopathy or control normal mice were also studied. RESULTS: Retinal pericyte-reactive antibodies induced cellular damage by activating complement in the serum. The antibody-injured pericytes had reduced efficacy in inhibiting T cells. Hyperglycemic culture conditions rendered pericytes more susceptible to antibody-mediated attack. CD38 was expressed in retinal pericytes, and upregulated by TNF-α and IFN-γ, and anti-CD38 antibodies induced pericyte cytotoxicity. Retinal pericytes sensitized with sera from chronic diabeticmice suffered significantly augmented cytotoxicity compared with those sensitized with sera from the control mice. CONCLUSIONS: The autoantibody-initiated complement activation could be a mechanism underlying the loss of function, and eventually, death of retinal pericytes in diabeticpatients, suggesting that inhibiting complement activation could be a novel therapeutic approach.
Authors: F Pomero; A Allione; E Beltramo; S Buttiglieri; F D'Alù; E Ponte; A Lacaria; M Porta Journal: Diabetologia Date: 2003-03-01 Impact factor: 10.122
Authors: R Mallone; E Ortolan; S Pinach; M Volante; M M Zanone; G Bruno; G Baj; T Lohmann; P Cavallo-Perin; F Malavasi Journal: Diabetologia Date: 2002-10-24 Impact factor: 10.122
Authors: Ulriche Denis; Marc Lecomte; Clarisse Paget; Daniel Ruggiero; Nicolas Wiernsperger; Michel Lagarde Journal: Free Radic Biol Med Date: 2002-07-15 Impact factor: 7.376
Authors: R Mallone; E Ortolan; G Baj; A Funaro; S Giunti; E Lillaz; F Saccucci; M Cassader; P Cavallo-Perin; F Malavasi Journal: Diabetes Date: 2001-04 Impact factor: 9.461
Authors: Jijun Xu; Lingjun Zhang; Mian Xie; Yan Li; Ping Huang; Thomas L Saunders; David A Fox; Richard Rosenquist; Feng Lin Journal: J Immunol Date: 2018-04-25 Impact factor: 5.422
Authors: Michael A Grassi; Vidhya R Rao; Siquan Chen; Dingcai Cao; Xiaoyu Gao; Patricia A Cleary; R Stephanie Huang; Andrew D Paterson; Rama Natarajan; Jalees Rehman; Timothy S Kern Journal: PLoS One Date: 2016-08-10 Impact factor: 3.240